A cellphone-sized device clipped to the waist just caught something a standard blood test almost always misses: hormone surges that spike while patients sleep and vanish before morning.
Story Snapshot
- A 2026 study tracked 60 high blood pressure patients for 24 hours using a wearable sensor instead of a single clinic blood draw.
- The device sampled fluid under the skin every 20 minutes, catching nighttime aldosterone bursts that routine testing never sees.
- Researchers from Bristol, Manchester, Bergen, Stockholm, and Athens built and tested the technology together.
- Primary aldosteronism, the hidden condition behind these surges, is already known to be badly underdiagnosed in hypertension patients.
A Waist-Worn Sensor Exposes What A Single Blood Draw Cannot
Doctors have long diagnosed primary aldosteronism using a single blood sample taken during a clinic visit. That snapshot approach works fine for conditions with steady hormone levels. But researchers publishing in Science Translational Medicine found the disorder behaves nothing like that. Patients produced hormone bursts throughout the day and, more strikingly, overnight while asleep, precisely when nobody is drawing blood.
The study fitted 60 patients with a device developed at the University of Bristol. It sat at the waist like a small phone and pulled fluid from just beneath the skin every 20 minutes, without a single needle stick after the initial setup. Over a full 24-hour stretch, it built a continuous hormone timeline instead of one isolated number.
What the timeline revealed matters. A single clinic draw can land during a quiet stretch and miss a surge entirely, or catch a spike and wrongly suggest constant overproduction. Continuous monitoring instead showed the true rhythm of the disease, with bursts concentrated overnight and normal readings at other times, a pattern a single test simply cannot capture.
Why This Gap Has Existed For So Long
Primary aldosteronism causes the adrenal glands to pump out too much aldosterone, a hormone that drives up blood pressure by making the body retain salt and water. Doctors have known for decades that it hides behind ordinary-looking hypertension diagnoses. One review called it “woefully underdiagnosed,” estimating that only about 1 in 550 affected patients in the United States actually gets identified and treated.
The reasons go beyond timing. Aldosterone and renin, the two hormones doctors compare to screen for the condition, are notoriously tricky to measure consistently across labs. Testing methods vary, reference ranges shift, and many primary care doctors simply do not order the screening test in the first place, even for patients whose blood pressure resists standard medication.
Germany offers a stark example of that screening gap. One estimate put the number of affected patients there at 2.5 million, yet only about 8 percent of hypertensive patients ever received proper testing for the disorder. Newer guidance from the Endocrine Society has pushed for broader screening, but commentary published this year admits that everyday practice still lags well behind the recommendation.
What Continuous Monitoring Could Change For Patients
Primary aldosteronism matters because it is treatable, sometimes with surgery that removes a small adrenal tumor and cures the high blood pressure outright. Missing the diagnosis means patients get stuck on standard blood pressure pills for years, controlling symptoms without ever touching the actual cause. Confirming the condition earlier could spare people from unnecessary long-term medication and reduce their risk of heart and kidney damage.
Not every expert agrees that finding more cases automatically means better outcomes. An earlier analysis pointed out that more sensitive screening tools raise the number of diagnosed cases without necessarily proving that the newly found cases are the surgically correctable kind that benefit most from treatment. That’s a fair caution worth keeping in mind as this technology moves toward wider use.
Related biosensor research is already underway, including a registered clinical trial testing wearable and nanoparticle-enhanced devices for tracking both aldosterone and cortisol in real time. If that work pans out, patients with stubborn high blood pressure may one day get a full day-and-night hormone readout instead of a single needle stick, giving doctors a far clearer picture of what’s actually driving their numbers up.
Sources:
sciencedaily.com, news-medical.net, medicaldaily.com, lavanguardia.com, birmingham.ac.uk, ccjm.org, aafp.org
